Phenacemide

Summary

Phenacemide (CHEMBL918) is an approved small molecule (ATC N03AX07); indicated across 1 condition including epilepsy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AX07
• Indications: 1 condition
• Chemistry: 178.19 Da · C9H10N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL918
Name	Phenacemide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4753
ATC	N03AX07
Molecular formula	C9H10N2O2
Molecular weight	178.19
InChIKey	XPFRXWCVYUEORT-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)CC(=O)NC(=O)N

IUPAC name: N-carbamoyl-2-phenylacetamide

Also known as: Fenacemida, NSC-39458, Phenacemide, Phenurone, Phenylacetyl-urea, (phenacemide)Phenylacetyl-urea, Phenylacetyl-urea (Phenacemide), SID26748194, PHENACEMIDE, SID144204878, SID170465322, phenacemide

Patent coverage: 2,016 distinct patent families (7,258 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).